Treatment satisfaction in the Sensor-Augmented Pump Therapy for A1C Reduction 3 (STAR 3) trial

Diabetic Medicine

Volumn 30, Issue 4, 2013, Pages 464-467

  Peyrot, Mark ^a   Rubin, R R ^b  

^a LOYOLA UNIVERSITY MARYLAND   (United States)

^b Behavioral Health Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; INSULIN DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CHILD; CONTROLLED STUDY; DAILY LIFE ACTIVITY; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE REGRESSION; PATIENT SATISFACTION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SOCIAL ASPECT; SOCIAL BURDEN; BLOOD; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; FEMALE; INSULIN INFUSION; MALE; METABOLISM; MIDDLE AGED; PERCEPTION; PSYCHOLOGICAL ASPECT;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE SELF-MONITORING; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN INFUSION SYSTEMS; INSULINS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PERCEPTION; YOUNG ADULT;

EID: 84880413071     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12079     Document Type: Article

References (9)

1. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN et al. for the STAR 3 Study Group. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010; 363: 311–319.
2. Rubin RR, Peyrot M STAR 3 Study Group. Health-related quality of life and treatment satisfaction in the Sensor-augmented Pump Therapy for A1c Reduction 3 (STAR 3) Trial. Diabetes Technol Ther 2012; 14: 143–151.
3. Peyrot M, Rubin RR. Validation and reliability of an instrument for assessing health-related quality of life: The Insulin Delivery System Questionnaire. Diabetes Care 2005; 28: 53–58.
4. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003; 41: 582–592.
5. Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care 2004; 27: 2495–2497.
6. Rubin RR, Peyrot M. Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care 2008; 31: 430–432.
7. Peyrot M, Rubin RR. Factors associated with persistence and resumption of insulin pen use for patients with type 2 diabetes. Diabetes Technol Ther 2011; 13: 43–48.
8. Peyrot M, Rubin RR. Perceived medication benefits and their association with interest in using inhaled insulin in type 2 diabetes: a model of patients’ cognitive framework. Patient Pref Adherence 2011; 5: 255–265.
9. Peyrot M, Rubin RR. How does treatment satisfaction work?: modeling determinants of treatment satisfaction and preference. Diabetes Care 2009; 32: 1411–1417.